CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

Cytokinetics (CYTK) provided guidance for corporate milestones expected to occur in 2025. Expected 2025 Milestones: Cardiac Muscle Programs: Aficamten: Advance go-to-market strategies and prepare ...

It might be easier to make sense of the recent fatal shooting of an insurance CEO, an act with ominous overtones about health care costs and insurance coverage, if any one aspect of health-care ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare ... release. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P.

Here are this week’s local business expansions, milestones and awards. EXPANDING University of Missouri Health Care’s Physician and Health Professional Wellness Program will offer statewide ...

According to the American Medical Association, it’s just 6 percent of health care spending. In other words, if insurers were to donate every cent of profit they made, your health care would ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

a district that backed Vice President Kamala Harris in the 2024 cycle — and your party asks you to support an agenda that takes health care benefits from poor families to finance tax breaks for ...